spbmedicalrecordsНовые Санкт-Петербургские врачебные ведомостиNew St. Petersburg Medical Records1609-2201Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова10.24884/1609-2201-2025-104-3-11-18spbmedicalrecords-101Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSСовременная терапия бронхиальной астмыModern treatment of bronchial asthmahttps://orcid.org/0000-0002-8574-6869ЕмельяновА. В.EmelianovA. V.

Емельянов Александр Викторович, доктор медицинских наук, профессор, заведующий кафедрой пульмонологии

Санкт-Петербург

Aleksandr V. Emelianov, Dr. of Sci. (Med.), Professor, Head of the Pulmonology Department

Saint Petersburg

aleksandr.emelyanov@szgmu.ruhttps://orcid.org/0000-0003-4616-3166ЛешенковаЕ. В.LeshenkovaE. V.

Лешенкова Евгения Владиславовна, кандидат медицинских наук, доцент кафедры пульмонологии

191015, Санкт-Петербург, ул. Кирочная, 41

Evgeniya V. Leshenkova, Cand. of Sci. (Med.), Associate Professor, Pulmonology Department

41, Kirochnaya St., Saint-Petersburg, 191015

Evgeniya.Leshenkova@szgmu.ruhttps://orcid.org/0000-0003-1544-4336СергееваГ. Р.SergeevaG. R.

Сергеева Галина Раисовна, кандидат медицинских наук, доцент кафедры пульмонологии

Санкт-Петербург

Galina R. Sergeeva, Cand. of Sci. (Med.), Associate Professor, Department of Pulmonology

Saint Petersburg

Galina.Sergeeva@szgmu.ruhttps://orcid.org/0000-0003-4464-5903ЦукановаИ. В.TsukanovaI. V.

Цуканова Инесса Витальевна, кандидат медицинских наук, ассистент кафедры пульмонологии

Санкт-Петербург

Inessa V. Tsukanova, Cand. of Sci. (Med.), Assistant Professor, Department of Pulmonology

Saint Petersburg

tsinessa@inbox.ruСеверо-Западный государственный медицинский университет им. И. И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation202511122025031118Copyright © Емельянов А.В., Лешенкова Е.В., Сергеева Г.Р., Цуканова И.В., 20252025Емельянов А.В., Лешенкова Е.В., Сергеева Г.Р., Цуканова И.В.Emelianov A.V., Leshenkova E.V., Sergeeva G.R., Tsukanova I.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.docved.ru/jour/article/view/101

В статье обсуждаются современные представления о лечении бронхиальной астмы, одного из самых частых и социально значимых респираторных заболеваний. Рассматриваются принципы его персонализированной терапии в зависимости от степени тяжести, уровня контроля и формы болезни в соответствии с последними международными и национальными рекомендациями.

Review is focused on modern treatment of asthma, one of the most prevalent and significant respiratory diseases in the world. Goals of long-term asthma management and different treatment tracks for symptoms control and risk reduction based on international and national recommendations are discussed.

бронхиальная астмаконтрольступенчатая терапияфенотипы астмыasthmacontrolstep of treatmentasthma phenotypesReferencesGlobal Strategy for Asthma Management and Prevention. Revised 2025. URL: https://www.ginasthma.org (дата обращения: 25.07.2025).Global Strategy for Asthma Management and Prevention. Revised 2025. URL: https://www.ginasthma.org (accessed: 25.07.2025).Бронхиальная астма. Национальные клинические рекомендации. Год пересмотра 2024. URL: https://cr.minzdrav.gov.ru/recomend/359_2 (дата обращения: 25.07.2025).Bronchial asthma. National clinical guidelines. 2024 URL: https://cr.minzdrav.gov.ru/recomend/359_2 (accessed: 25.07.2025). (In Russ.).Prieto L., Badiola C., Villa J. R. et al. Asthma Control: Do Patients’ and Physicians’ Opinions Fit in with Patients’ Asthma Control Status? // Journal of Asthma. 2007. Vol. 44, № 6. P. 461–467. https://doi.org/10.1080/02770900701421989.Prieto L., Badiola C., Villa J. R. et al. Asthma Control: Do Patients’ and Physicians’ Opinions Fit in with Patients’ Asthma Control Status? Journal of Asthma. 2007;44:461–467. https://doi.org/10.1080/02770900701421989.Urrutia I., Plaza V., Pascual S. et al. Asthma control and concordance of opinions between patients and pulmonologists // Journal of Asthma. 2013. Vol. 50, № 8. P. 877–883. https://doi.org/10.3109/02770903.2013.819886.Urrutia I., Plaza V., Pascual S. et al. Asthma control and concordance of opinions between patients and pulmonologists. Journal of Asthma. 2013;50(8):877–883. https://doi.org/10.3109/02770903.2013.819886.Stridsman C., Axelsson M., Warm K., Backman H. Uncontrolled asthma occurs in all GINA treatment steps and is associated with worse physical health — A report from the OLIN adult asthma cohort // Journal of Asthma. 2020. P. 1–16. https://doi.org/10.1080/02770903.2020.1713150.Stridsman C., Axelsson M., Warm K., Backman H. Uncontrolled asthma occurs in all GINA treatment steps and is associated with worse physical health — A report from the OLIN adult asthma cohort. Journal of Asthma. 2020:1–16. https://doi.org/10.1080/02770903.2020.1713150.Thomas D., McDonald V. M., Pavord I. D., Gibson P. G. Asthma remission: what is it and how can it be achieved? // The European Respiratory Journal. 2022. Vol. 60, № 5. P. 2102583. https://doi.org/10.1183/13993003.02583-2021.Thomas D., McDonald V. M., Pavord I. D., Gibson P. G. Asthma remission: what is it and how can it be achieved? The European Respiratory Journal. 2022;60(5):2102583. https://doi.org/10.1183/13993003.02583-2021.Lotvall J., Akdis C.A., Bacharier L. B. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome // JACI. 2011. Vol. 127. P. 355–360. https://doi.org/10.1016/j.jaci.2010.11.037.Lotvall J., Akdis C.A., Bacharier L. B. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. JACI. 2011;127:355–360. https://doi.org/10.1016/j.jaci.2010.11.037.Федосеев Г. Б., Трофимов В. И., Петрова М. А. Многоликая бронхиальная астма, диагностика, лечение и профилактика. Санкт-Петербург, Нордмедиздат, 2011. 44 с.Fedoseyev G. B., Trofimov V. I., Petrova M. A. The many-sided bronchial asthma, diagnosis, treatment and prevention. Saint-Peterburg, Nordmedizdat, 2011. 344 p. (In Russ.).Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA) // ARIA. At a glance pocket reference, 1st Edition. 2007. 6 p.Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA). ARIA. At a glance pocket reference, 1st Edition. 2007. 6 p.Sobieraj D. M., Weeda E. R., Nguyen E. et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma. A Systematic Review and Meta-analysis // JAMA. 2018. Vol. 319, № 14. P. 1485–1496. https://doi.org/10.1001/jama.2018.2769.Sobieraj D. M., Weeda E. R., Nguyen E. et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma. A Systematic Review and Meta-analysis. JAMA. 2018;319(14):1485–1496. https://doi.org/10.1001/jama.2018.2769.Lee L. A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial // The Lancet Respiratory Medicine. 2021. Vol. 9, № 1. P. 69–84. https://doi.org/10.1016/s2213-2600(20)30389-1.Lee L. A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine. 2021;9(1):69–84. https://doi.org/10.1016/s2213-2600(20)30389-1.Woodcock A., Vestbo J., Bakerly N. D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial // The Lancet. 2017. Vol. 390, № 10109. P. 2247–2255. https://doi.org/10.1016/s0140-6736(17)32397-8.Woodcock A., Vestbo J., Bakerly N. D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. The Lancet. 2017;390(10109):2247–2255. https://doi.org/10.1016/s0140-6736(17)32397-8.McCracken J., Tripple J., Calhoun W. Biologic therapy in the management of asthma // Curr Opin Allergy Clin Immumol. 2016. Vol. 16, № 4. P. 375–382. https://doi.org/10.1097/aci.0000000000000284.McCracken J., Tripple J., Calhoun W. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immumol. 2016;16(4):375–382. https://doi.org/10.1097/aci.0000000000000284.Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy // Drug design, development and therapy. 2018. Vol. 12. P. 619–628. https://doi.org/10.2147/dddt.s155307.Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug design, development and therapy. 2018;12:619–628. https://doi.org/10.2147/dddt.s155307.Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study // Clinical Therapeutics. 2016. Vol. 38, № 9. P. 2058–2070. https://doi.org/10.1016/j.clinthera.2016.07.010.Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical Therapeutics. 2016;38(9):2058–2070. https://doi.org/10.1016/j.clinthera.2016.07.010.Castro M., Corren J., Pavord I. D. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma // N Engl J Med. 2018. Vol. 378. P. 2486–2496. https://doi.org/10.1056/nejmoa1804092.Castro M., Corren J., Pavord I. D. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486–2496. https://doi.org/10.1056/nejmoa1804092.Agache I., Akdis C., Akdis M. et al. EAACI Biologicals Guidelines-Recommendations for severe asthma // Allergy. 2021. Vol. 76, № 1. P. 14–44. https://doi.org/doi.org/10.1111/all.14425.Agache I., Akdis C., Akdis M. et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021;76(1):14–44. https://doi.org/doi.org/10.1111/all.14425.Тяжелая бронхиальная астма. Клинические рекомендации Ассоциации русскоговорящих специалистов в области респираторной медицины. М., 2018. URL: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (дата обращения: 25.07.2025).Severe bronchial asthma. Clinical guidelines of the Association of Russian-speaking specialists in the respiratory medicine. Мoscow, 2018. URL: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (accessed: 25.07.2025). (In Russ.).Bousquet J., Brusselle G., Buhl R. et al. Care pathways for the selection of a biologic in severe asthma // Eur Respir J. 2017. Vol. 50. P. 1701782. https://doi.org/10.1183/13993003.01782-2017.Bousquet J., Brusselle G., Buhl R. et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50:1701782. https://doi.org/10.1183/13993003.01782-2017.Menzies-Gow A., Corren J., Bourdin A. et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma // N Engl J. 2021. Vol. 384. P. 1800–1809. https://doi.org/10.1056/nejmoa2034975.Menzies-Gow A., Corren J., Bourdin A. et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J. 2021;384:1800–1809. https://doi.org/10.1056/nejmoa2034975.Wechsler M. E., Ruddy M. K., Pavord J. D. et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma // N Engl J Med. 2021. Vol. 385, № 18. P. 1656–1668. https://doi.org/10.1056/nejmoa2024257.Wechsler M. E., Ruddy M. K., Pavord J. D. et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021;385(18):1656–1668. https://doi.org/10.1056/nejmoa2024257.Kelsen S. G., Agache J. O., Soong W. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial // J Allergy Clin Immunol. 2021. Vol. 148, № 3. P. 790–798. https://doi.org/10.1016/j.jaci.2021.03.044.Kelsen S. G., Agache J. O., Soong W. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790–798. https://doi.org/10.1016/j.jaci.2021.03.044.Рациональная терапия бронхиальной астмы: руководство для врачей / под ред. А. В. Емельянова. М.: ГЭОТАР-Медиа, 2025. 280 с.: ил.Emelyanov A. V. Rational therapy of bronchial asthma. Moscow, GEOTAR-Media, 2025. 280 p.: ill. (In Russ.). https://doi.org/10.33029/9704-8825-6-RTA-2025-1-280.Jarjour N. N., Erzurum S. C., Bleecker E. R. et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program // Am J Respir Crit Care Med. 2012. Vol. 185, № 4. P. 356–362. https://doi.org/10.1164/rccm.201107-1317pp.Jarjour N. N., Erzurum S. C., Bleecker E. R. et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185(4):356–362. https://doi.org/10.1164/rccm.201107-1317pp.Сергеева Г. Р., Емельянов А. В., Коровина О. В. и др. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015. Т. 12. С. 22–27. https://doi.org/10.17116/terarkh2015871226-31.Sergeeva G. R., Emelyanov A. V., Korovina O. V. et al. Severe asthma: Characteristics of patients in clinical practice. Terapevticheskii Arkhiv. 2015;12:22–27. (In Russ.). https://doi.org/10.17116/terarkh2015871226-31.Федосеев Г. Б., Трофимов В. И., Шапорова Н. Л. и др. В поисках истины: что такое бронхиальная астма? // Пульмонология. 2015. Т. 25, № 1. С. 5–18. https://doi.org/10.18093/0869-0189-2015-25-1-5-18.Fedoseev G. B., Trofimov V. I., Shaporova N. L. et al. Searching the truth: what is bronchial asthma? Pulmonologiya. 2015;25(1):5–18. (In Russ.). https://doi.org/10.18093/0869-0189-2015-25-1-5-18.Rajan J. P., Wineinger N. E., Stevenson D. D., White A. A. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature // J Allergy Clin Immunol. 2015. Vol. 135, № 3. P. 676. https://doi.org/10.1016/j.jaci.2014.08.020.Rajan J. P., Wineinger N. E., Stevenson D. D., White A. A. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676. https://doi.org/10.1016/j.jaci.2014.08.020.Сергеева Г. Р., Емельянов А. В., Лешенкова Е. В. и др. Фиксированная обструкция дыхательных путей у больных бронхиальной астмой // Пульмонология. 2020. Т. 30, № 3. С. 295–304. https://doi.org/10.18093/0869-0189-2020-30-3-295-304.Sergeeva G. R., Emel’yanov A. V., Leshenkova E. V. et al. Fixed airflow obstruction in patients with asthma. Pulmonologiya. 2020;30(3):295–304. (In Russ.). https://doi. org/10.18093/0869-0189-2020-30-3-295-304.ten Brinke A., Zwinderman A. H., Sterk P. J. et al. Factors associated with persistent airflow limitation in severe asthma // Am J Respir Crit Care Med. 2001. Vol. 164, № 5. P. 744–748. https://doi.org/10.1164/ajrccm.164.5.2011026.ten Brinke A., Zwinderman A. H., Sterk P. J. et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164(5):744–748. https://doi.org/10.1164/ajrccm.164.5.2011026.Lee J. H., Haselkorn T., Borish L. et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study // Chest. 2007. Vol. 132, № 6. P. 1882–9. https://doi.org/10.1378/chest.07-0713.Lee J. H., Haselkorn T., Borish L. et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132:1882–9. https://doi.org/10.1378/chest.07-0713.Pappi A., Singh D., Virchow J. C. et al. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER // Clin Transl Allergy. 2022. Vol. 12, № 4. P. e12145. https://doi.org/10.1002/clt2.12145.Pappi A., Singh D., Virchow J. C. et al. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022;12(4):e12145. https://doi.org/10.1002/clt2.12145.Peters U., Dixon A. E., Forno E. Obesity and asthma // JACI. 2018. Vol. 141, № 4. P. 1169–1179. https://doi.org/10.1016/j.jaci.2018.02.004.Peters U., Dixon A. E., Forno E. Obesity and asthma. JACI. 2018;141(4):1169–1179. https://doi.org/10.1016/j.jaci.2018.02.004.Dixons A., Que L. Obesity and Asthma.Semin Respir // Crit Care Med. 2022. Vol. 43, № 05. P. 662–674. https://doi.org/10.1055/s-0042-1742384.Dixons A., Que L. Obesity and Asthma.Semin Respir. Crit Care Med. 2022;43(05):662–674. https://doi.org/10.1055/s-0042-1742384.Menzies-Gow A., Gurnell M., Heaney L. G. et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study // Lancet Respir Med. 2022. Vol. 10, № 1. P. 47–58. https://doi.org/10.1016/s2213-2600(21)00352-0.Menzies-Gow A., Gurnell M., Heaney L. G. et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. https://doi.org/10.1016/s2213-2600(21)00352-0.Romero-Tapia S. J., Priego C. G., Del-Río-Navarro B. E., Sánchez-Solis M. Advances in the Relationship between Respiratory Viruses and Asthma // J. Clin. Med. 2023. Vol. 12. P. 5501. https://doi.org/10.3390/jcm12175501.Romero-Tapia S. J., Priego C. G., Del-Río-Navarro B. E., Sánchez-Solis M. Advances in the Relationship between Respiratory Viruses and Asthma. J. Clin. Med. 2023;12:5501. https://doi.org/10.3390/jcm12175501.Crapo R. O., Casaburi R., Coates A. L. et al. Guidelines for Methacholine and Exercise Challenge Testing—1999 // American Journal of Respiratory and Critical Care Medicine. 2000. Vol. 161, № 1. P. 309–329. https://doi.org/10.1164/ajrccm.161.1.ats11-99.Crapo R. O., Casaburi R., Coates A. L. et al. Guidelines for Methacholine and Exercise Challenge Testing—1999. American Journal of Respiratory and Critical Care Medicine. 2000;161(1): 309–329. https://doi.org/10.1164/ajrccm.161.1.ats11-99.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers // J Allergy Clin Immun. 2013. Vol. 131, № 3. P. 763–771. https://doi.org/10.1016/j.jaci.2012.12.673.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immun. 2013;131(3):763–771. https://doi.org/10.1016/j.jaci.2012.12.673.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers // J Allergy Clin Immun. 2013. Vol. 131, № 3. P. 763–771. https://doi.org/10.1016/j.jaci.2012.12.673.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers // J Allergy Clin Immun. 2013. Vol. 131, № 3. P. 763–771. https://doi.org/10.1016/j.jaci.2012.12.673.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immun. 2013;131(3):763–771. https://doi.org/10.1016/j.jaci.2012.12.673.Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immun. 2013;131(3):763–771. https://doi.org/10.1016/j.jaci.2012.12.673.

The authors declare that there are no conflicts of interest present.